Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Outstanding (Weighted Average): 2017-2025

Historic Shares Outstanding (Weighted Average) for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $32.2 million.

  • Dianthus Therapeutics' Shares Outstanding (Weighted Average) rose 9.65% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year increase of 9.65%. This contributed to the annual value of $29.6 million for FY2024, which is 99.74% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Shares Outstanding (Weighted Average) stood at $32.2 million, which was up 0.09% from $32.2 million recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $32.2 million for Q3 2025, and its period low was $3.7 million during Q1 2022.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $29.3 million (2024), whereas its average is $21.8 million.
  • Data for Dianthus Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 674.32% (in 2024) over the last 5 years.
  • Dianthus Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $3.8 million in 2022, then surged by 291.52% to $14.8 million in 2023, then soared by 99.74% to $29.6 million in 2024, then rose by 9.65% to $32.2 million in 2025.
  • Its last three reported values are $32.2 million in Q3 2025, $32.2 million for Q2 2025, and $32.1 million during Q1 2025.